FDA data Registry peer set 1 peer

Alternatives to alirocumab

1 same-class SPL records vs alirocumab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Praluent

PCSK9 Inhibitor Prescription 1 alternative found

About alirocumab

Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.

Used for: Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.

1 PCSK9 Inhibitor peers (wide set)

Compare alirocumab vs evolocumab side-by-side →

alirocumab vs evolocumab · FAERS reaction fields

FAERS top-reaction field "Injection Site Pain" shows the widest count spread between alirocumab and evolocumab in this extract (9,062-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect alirocumab evolocumab
Myalgia 1,655 5,267
Product Dose Omission 1,364 -
Injection Site Pain 1,278 10,340
Muscle Spasms 1,162 3,171
Arthralgia 1,053 3,922
Fatigue 1,018 3,872
Pain 945 2,973
Pain In Extremity 935 3,373

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

alirocumab peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for PCSK9 Inhibitor: 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside alirocumab?
This registry lists 1 PCSK9 Inhibitor medication records beside alirocumab, including evolocumab. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide PCSK9 Inhibitor peer set (1 records)

alirocumab (Praluent) sits in a wide PCSK9 Inhibitor peer set (1 of 1 class peers shown). Labeled indication field for alirocumab: Praluent is used to lower LDL cholesterol (bad cholesterol).

Top FAERS reaction fields for alirocumab total 11,050 reports across 10 reactions, set beside evolocumab. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full alirocumab profile →

Field note for alirocumab: see also the generic vs brand label guide when reading Praluent SPL strings.